| 2018-03-13 16:16:33|
VTL 16:16 03/13 03/13/18
Vital Therapies CEO says nears completion for VTL-308
"As VTL-308 nears completion, I am proud of the job our team has done in designing and running this pivotal trial," said Russell J. Cox, the company's CEO. "Not only do baseline characteristics of subjects continue to track closely to the reference population, but also, blended event rates were found to be consistent with our modeled expectations. We look forward to reporting topline results in the third quarter, and in the event of a positive outcome, preparing to file a biologics license application next year."